Skip to main content

Advertisement

Table 2 Summary of subgroup analysis

From: Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis

Categories Number of studies Number of patients Model HR (95% CI) I2 (%) P h Z P
Study region
 Asian 4 1016 Fixed 3.12 (0.54–5.20) 31 0.23 4.85 <  0.001
 Non-Asian 5 1593 Random 3.03 (1.96–4.69) 51 0.09 4.98 <  0.001
Sample size
  < 200 4 415 Fixed 1.84 (1.25–2.71) 0 0.78 3.07 0.002
  ≥ 200 5 2194 Fixed 4.04 (2.98–5.50) 0 0.8 8.92 <  0.001
FIGO stage
 I–IV 8 2541 Fixed 2.98 (2.33–3.82) 44 0.08 8.66 <  0.001
 III–IV 1 68 Fixed 3.05 (1.06–8.80) NA NA 2.06 0.04
Cut-off value (×109/L)
 350 1 108 Fixed 1.37 (0.30–6.17) NA NA 0.41 0.68
 400 8 2501 Fixed 3.05 (2.39–3.89) 39 0.12 8.95 <  0.001
Analysis method
 Multivariate 5 1053 Fixed 2.47 (1.78–4.42) 43 0.13 5.44 <  0.001
 Univariate 4 1556 Fixed 3.76 (2.63–5.37) 0 0.46 7.25 <  0.001
  1. Random-effects model was used when P-value for heterogeneity test < 0.1; otherwise, fixed-effects model was used
  2. Abbreviations: FIGO International Federation of Gynecology and Obstetrics, HR hazard ratio, CI confidence interval, Ph, P-value for heterogeneity based on Q test, P P-value for statistical significance based on Z test, NA Not applicable